Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does concentrated growth factor provide better outcomes than platelet-rich fibrin or arthrocentesis in the management of temporomandibular disorders?

International journal of oral and maxillofacial surgery·2026
Same author

From Ground to Excited State: Revealing Bond Polarity Change via K<sup>-2</sup>V Spectroscopy and Brillouin Inverse Theorem (BIT).

The journal of physical chemistry letters·2025
Same author

Biosafety and Withdrawal Period of In-Feed Administered Antiparasitic Drug Emamectin Benzoate in Cirrhinus mrigala (Hamilton, 1822).

Journal of veterinary pharmacology and therapeutics·2025
Same author

Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study.

Oral oncology·2024
Same author

Modified realist evaluation of a complex, multi-centred, multi-intervention programme.

Journal of public health (Oxford, England)·2023
Same author

UNDERSTANDING THE LONG-TERM INTERPLAY BETWEEN GLUCOCORTICOIDS, PARATHYROID HORMONE LEVELS, AND OSTEOPOROSIS IN PATIENTS.

Georgian medical news·2023
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.7K

Optimizing Central Nervous System Drug Development Using Molecular Imaging.

R J Hargreaves1, J Hoppin2, J Sevigny1

  • 1Biogen, Cambridge, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|April 15, 2015
PubMed
Summary
This summary is machine-generated.

Multimodality fusion imaging and molecular imaging biomarkers accelerate central nervous system (CNS) drug development. These tools enable early disease detection and personalized treatment strategies for neurodegenerative disorders.

More Related Videos

Molecular Imaging of Human Brain Organoids Using Mass Spectrometry
08:04

Molecular Imaging of Human Brain Organoids Using Mass Spectrometry

Published on: September 27, 2024

1.5K
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

919

Related Experiment Videos

Last Updated: Apr 15, 2026

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.7K
Molecular Imaging of Human Brain Organoids Using Mass Spectrometry
08:04

Molecular Imaging of Human Brain Organoids Using Mass Spectrometry

Published on: September 27, 2024

1.5K
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
07:45

Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis

Published on: October 25, 2024

919

Area of Science:

  • Biomedical Engineering
  • Neuroscience
  • Pharmacology

Background:

  • Multimodality fusion imaging advances offer new insights into disease systems biology.
  • Molecular imaging biomarkers streamline central nervous system (CNS) drug development, enhancing efficiency and ROI.
  • Current neurodegenerative disease treatments often begin after overt symptoms appear.

Purpose of the Study:

  • To highlight the role of multimodality fusion imaging in understanding disease.
  • To emphasize the benefits of molecular imaging biomarkers in CNS drug development.
  • To explore the potential of CNS imaging biomarkers for early detection and treatment of neurodegenerative diseases.

Main Methods:

  • Review of current advancements in multimodality fusion imaging technologies.
  • Analysis of the application and impact of molecular imaging biomarkers in CNS drug development.
  • Discussion of the potential for CNS imaging biomarkers in early disease intervention.

Main Results:

  • Molecular imaging biomarkers reduce drug development cycle times and improve research efficiency.
  • Imaging biomarkers aid in selecting optimal drug candidates, dosages, and patient cohorts.
  • CNS imaging biomarkers can facilitate early detection, prevention, and tracking of neurodegenerative diseases.

Conclusions:

  • Multimodality fusion imaging and CNS imaging biomarkers are pivotal for advancing therapeutic development.
  • These technologies enable a paradigm shift towards proactive and personalized neurodegenerative disease management.
  • Early intervention strategies driven by imaging biomarkers promise improved patient outcomes.